Positive phase 3 head-to-head data results from DELTA FORCE trial comparing delgocitinib cream with alitretinoin capsules in adults with severe chronic hand eczema (CHE). Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure.
Delgocitinib cream is an investigational, first-in-class, topical pan-Janus kinase (JAK) inhibitor for CHE. It inhibits the activation of JAK-STAT signaling, which plays a key role in the pathogenesis of CHE.